PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
http://www.peervoice.com
Ana C. Garrido-Castro, MD / Sarah L. Sammons, MD - TROP2-Directed Antibody-Drug Conjugates for Breast Cancer: The Clinical Significance of the Construct
Visit https://www.peervoice.com/JJH860 to view the entire programme with slides. After completing “Ana C. Garrido-Castro, MD / Sarah L. Sammons, MD - TROP2-Directed Antibody-Drug Conjugates for Breast Cancer: The Clinical Significance of the Construct”, participants will be able to: Differentiate between approved and emerging TROP2-directed antibody-drug conjugates (ADCs); Summarize the clinical evidence for TROP2-directed ADCs in patients with hormone receptor-positive (HR+)/HER2-low or negative breast cancer and triple-negative breast cancer (TNBC); and Identify adverse event (AE) profiles of current and emerging TROP2-directed ADCs.